---
title: "Medicenna Reports Promising ABILITY-1 Trial Results and Strong Financial Position for 2025"
date: "2025-02-14 00:08:32"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioMedicenna Therapeutics Corp ( (TSE:MDNA) )..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1549769756-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Medicenna Therapeutics Corp ( [(TSE:MDNA)](https://www.tipranks.com/stocks/tse:mdna) ) has provided an update.

Medicenna Therapeutics Corp announced its financial results for the third quarter of fiscal 2025, highlighting significant progress in its ABILITY-1 trial, which combines MDNA11 with KEYTRUDA. The trial demonstrated a 78% disease control rate with promising responses, including complete and partial responses in patients with treatment-refractory tumors. The company also reported strong financial backing, ensuring operations are funded through mid-2026, and shared its excitement about upcoming milestones that could further validate its clinical development program.

**More about Medicenna Therapeutics Corp**

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines, which are advanced therapeutics designed to improve the immune system’s ability to fight cancer. The company operates in the biotechnology industry and is targeting a range of tumor types with its innovative therapies.

**YTD Price Performance:** -20.13%

**Average Trading Volume:** 67,432

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** C$99.33M

For a thorough assessment of MDNA stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/tse:mdna/stock-analysis).

Trending Articles:
------------------

* [Jensen Huang’s Net Worth: The Billionaire Who Leads the World’s Largest Chip Company Nvidia](https://www.tipranks.com/news/jensen-huangs-net-worth-the-billionaire-who-leads-the-worlds-largest-chip-company-nvidia)
* [Super Micro (SMCI) Wins a New Street-High Price Target from Northland Securities](https://www.tipranks.com/news/super-micro-smci-wins-a-new-street-high-price-target-from-northland-securities)
* [3 Penny Stocks to Watch Now, 2/13/25](https://www.tipranks.com/news/3-penny-stocks-to-watch-now-2-13-25)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/medicenna-reports-promising-ability-1-trial-results-and-strong-financial-position-for-2025)
